Effect of renal impairment on the pharmacokinetics of antimony in hamsters

References

• Al-Jaser, M. H., El-Yazigi, A. & Croft, S. L. (1995). Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharmaceutical Research, 12,113–116.
   PubMed Web of Science ®Google Scholar
• Alrajhi, A. A., Inbahim, E. F., de Vol, E., Khairat, M., Faris, R. & Maguire, J. (2002). Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New England Journal of Medicine, 346,891–895.
   PubMed Web of Science ®Google Scholar
• Antezana, G., Zeballo, R., Mendoza, C., Lyevre, P., Valda, L., Cardenas, F., Noriega, I. Ugarte, H. & Dedet, J. P.(1992). Electrogardiographic alterations during treatment of mucoucutaneous leishmaniasis with meglumine antimonite and allpurinol. Transac-tions of the Royal Society of Tropical Medicine and Hygiene, 86, 31-33.
   Google Scholar
• Appenroth, D., Lupp, A., Kriegsmann, J., Sawall, S., Splinther, J. Sommer, M., Stien, G. & Fleck, C. (2001). Temporary warm ischemia, 5/6 nephrectomy and single uranyl nitrate administration — compari-son of three models intended to cause renal fibrosis in rats. Experimental and Toxicologic Pathology, 53, 316–324.
   Google Scholar
• Berman, J. D., Gallalee, J. F. & Gallalee, J. V. (1988). Pharmacokinetics of pentavalent antimony (Pent-ostam) in hamsters. American Journal of Tropical Medicine and Hygiene, 39,41–45.
   PubMed Web of Science ®Google Scholar
• Brophy, D. F. (2001). Acute renal failure. In Applied Therapeutics, the Clinical Use of Drugs, 7th Edn, eds Koda-Kimble, M. A. & Young, L. Y. pp. 1-2 of Chapter 29. New York: Lippincott, Williams & Wilkins.
   Google Scholar
• Chulay, J. D., Fleckenstien, L. & Smith, D. H. (1988). Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimonite. Transactions of the Royal Society of Tropical Medicine and Hygiene, 82,69–72.
   PubMed Web of Science ®Google Scholar
• Delagado, J., Macias, J., Pineda, J. A., Corzo, J. E., Gonzalez-Moreno, M. P., de la Rosa, R., Sanchez-Quijano, A., Leal, M. & Lissen, E. (1999). High frequency of serious side effects from meglumine antimonite given without an upper limits dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1 -infected patients. American Journal of Tropical Medicine and Hygiene, 61, 766–769.
   PubMed Web of Science ®Google Scholar
• Gibaldi, M. & Perrier, D. (1982). Pharmacokinetics, 2nd Edn. New York: Marcel Dekker.
   Google Scholar
• Hantson, P., Luyasu, S., Haufroid, V. B. & Lambert, M. (2000). Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy. Pharmacotherapy, 20,1141–1143.
   PubMed Web of Science ®Google Scholar
• Hepburn, N. C. (2001). Management of cutaneous leishmaniasis. Current Opinion in Infectious Diseases, 14,151–154.
   PubMed Web of Science ®Google Scholar
• Hudson, J. Q. & Johnson, C. A. (2001). Chronic renal failure. In Applied Therapeutics, the Clinical Use of Drugs, 7th Edn, eds Koda-Kimble, M. A. & Young, L. Y. p. 2 of Chapter 30. New York: Lippincott, Williams & Wilkins.
   Google Scholar
• Lazanas, M. C., Tsekes, G. A., Papandreous, S., Harhalakis, N., Scandali, A., Niiforakis, E. & Saroglou, G. (1993). Liposomal amphotericin B for the treatment of AIDS patients unresponsive to antimonial compounds. AIDS, 7, 1018-1019.
   Google Scholar
• Rai, U. S., Kumar, H. & Kumar, U. (1994). Renal dysfunction in patients of kala-azar treated with sodium antimony gluconate. Journal of the Association of Physicians of India, 42,383.
   PubMedGoogle Scholar
• Rees, P. H., Keating, M. I., Kager, P. A. & Hockameyer, W. T. (1980). Renal clearance of pentavalent anti-mony (sodium stibogluconate). Lancet, II, 226–229.
   PubMed Web of Science ®Google Scholar
• Sampaio, R. N., de Paula, C. D., Sampaio, J. H., Furtado, R. de S., Leal, P. P. & Rosa, T. T. Rodrigues, M. E. & Veiga, J. P. (1997). The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg SbV/kg/day, 12/12 hr, for 30 days in the muco-cutaneous form of leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 30, 457-463.
   Google Scholar
• Soto, J., Buffet, P., Grogl, M. & Berman, J. (1994). Successful treatment of Colombian cutaneous leish-maniasis with four injections of pentamidine. American Journal of Tropical Medicine and Hygiene, 50,107–111.
   PubMed Web of Science ®Google Scholar
• Sundar, S., Argwal, G., Rai, M., Makharia, M. K. & Murray, H. W. (2001). Treatment of Indian visceral leishmaniasis with single or daily infusion of low dose liposomal amphotericin B: randomized trial. British Medical Journal, 323,419–422.
   PubMed Web of Science ®Google Scholar
• Sundar, S., Jha, T. K., Sindermann, H., Junge, K., Bachmann, P. & Berman, J. (2003). Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatric Infectious Disease Journal, 22,434–438.
   PubMed Web of Science ®Google Scholar
• Veiga, J. P., Wolff, E. R., Sampaio, R. N. & Marsden, P. D. (1983). Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials. Lancet, II, 569.
   PubMed Web of Science ®Google Scholar
• Veiga, J. P., Khanam, R., Rosa, T. T., Junqueira Jr, L. F., Brant, P. C., Friedman, H. & Marsden P. D. (1990). Pentavalent antimonial nephrotoxicity in the rat. Revista do Institut° de Medicina Tropical de Scio Paulo, 32, 304-309.
   Google Scholar
• World Health Organization (1984). The Leishmaniases. Technical Report Series No 71. Geneva: WHO.
   Google Scholar
• Zijlstra, E. E., Siddig Ali, M., El-Hassan, A. M., Hofland, H. W., El-Toum, I., Satti, M. & Ghalib, H. W. (1993). Treatment of kala-azar in the Sudan with sodium stibogluconate, a randomized trial of three dosage regimens. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87,307–309.
   PubMed Web of Science ®Google Scholar